Drug Profile
Research programme: purinergic receptor antagonists - Evotec SE
Alternative Names: P2X7 receptor antagonists - Evotec SE; P2X2/3 antagonists; P2X2/3 antagonists - Evotec SE; P2X3 antagonists; P2X3 antagonists - Evotec SELatest Information Update: 25 Sep 2019
Price :
$50
*
At a glance
- Originator Renovis
- Developer Evotec SE
- Class Small molecules
- Mechanism of Action Purinergic P2 receptor antagonists; Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain; Urinary incontinence
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Urinary-incontinence in Germany
- 06 Mar 2007 Preclinical trials in Urinary incontinence in USA (unspecified route)